Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 204-068-4 | CAS number: 115-18-4
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 04 Feb 1991 to 18 Mar 1991 (experimental phase)
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: GLP guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 994
- Report date:
- 1994
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Version / remarks:
- adopted 1981
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 2-methylbut-3-en-2-ol
- EC Number:
- 204-068-4
- EC Name:
- 2-methylbut-3-en-2-ol
- Cas Number:
- 115-18-4
- Molecular formula:
- C5H10O
- IUPAC Name:
- 2-methylbut-3-en-2-ol
- Details on test material:
- - Name of test material (as cited in study report): 2-methylbut-3-en-2-ol-
- Physical state: colourless liquid
- Batch No.: 79-1089 from 26 Oct 1989
- Purity : 97.9 %
- Storage conditions: Room temperature
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Dr. Karl Thomae GmbH, Biberach/Riss, D
- Age at study initiation: 42 days at the start of application
- Weight at study initiation: mean 187 g (males), 161 g (females)
- Housing: singly in type DK III stainless steel wire cages from Becker & Co., Castrop-Rauxel, D (floor area about 800 cm2)
- Diet (e.g. ad libitum): Kliba rats/mice/ hamsters maintenance diet, "A" 343 meal, Klingentalmuehle AG, Kaiseraugst, Switzerland; ad libitum
- Water (e.g. ad libitum): drinking water; ad libitum
- Acclimation period: 10 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24
- Humidity (%): 30 - 70
- Photoperiod (hrs dark / hrs light): 12 / 12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- olive oil
- Remarks:
- DAB 9
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS:
The doses were prepared daily. The test substance was weighed and diluted to the appropriate volume with olive oil DAB 9. The doses were dissolved using a magnetic stirring apparatus. The doses were administered using syringes (3 cc Syringe; Fa. Becton Dickinson & Co., USA)
VEHICLE
- Concentration in vehicle: 0.6, 3, 15 g/100ml
- Amount of vehicle (if gavage): 5 mL /kg bw - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Gas chromatography was used to determine the content of 2-Methylbuten-3-ol-2 of the undiluted test substance and of the doses. Hydrogen-nuclear magnetic resonance confirmed the identity of the test substance.
- Duration of treatment / exposure:
- 4 weeks
- Frequency of treatment:
- 5 times per week
Doses / concentrations
- Remarks:
- Doses / Concentrations:
30, 150 and 750 mg/kg body weight (Analytical checks of the concentrations confirmed that the concentrations were within an acceptable range (93 - 103% of the target concentration).
Basis:
actual ingested
- No. of animals per sex per dose:
- 5
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The doses for this study were chosen on the basis of previous investigations. In the first pretest, 2-methylbut-3-en-2-ol was administered in olive oil 11 times by gavage to each 3 male and 3 female Wistar rats at doses of 100 and 500 mg/kg body weight. A group of 3 male and 3 female animals served as vehicle control and received olive oil only. In order to find a dose with clear and persistent findings, a second pretest, 2-methylbut-3-en-2-ol was administered in olive oil at doses of 15 and 1.000 mg/kg body weight. The test substance was administered by gavage 11 times each to 3 male and 3 female Wistar rats. Vehicle control was a group each of 3 males and 3 females which received DAB 9 olive oil only. Detailed results were described under “Additional details on results”.
Examinations
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: The general state of health of the animals was checked twice a day (Monday to Friday) and once a day (Saturdays, Sundays and public holidays). Furthermore the animals were checked for the appearance of clinical signs before and after each test substance administration
BODY WEIGHT: Yes
- Time schedule for examinations: before the start of the administration period in order to randomize the animals. During the conduct of the study, the body weight was determined on day 0 (start of administration period) and thereafter in weekly intervals
FOOD CONSUMPTION:
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/day: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No
OPHTHALMOSCOPIC EXAMINATION: No
HAEMATOLOGY: Yes
- Time schedule for collection of blood: 28 days after the beginning of administration period
- Anaesthetic used for blood collection: No
- Animals fasted: No
- How many animals: all surviving animals per test group and sex
- Parameters checked in table were examined: leukocytes, erythrocytes, hemoglobin, hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelets, differential blood count, thromboplastin time
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: 28 days after the beginning of administration period
- Animals fasted: No
- How many animals: all surviving animals per test group and sex
- Parameters checked in table were examined: alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, serum-glutamyltransferase, sodium, potassium, chloride, inorganic phosphate, calcium, urea, creatinine, glucose, total bilirubin, total protein, albumin, globulins, triglycerides, cholesterol, magnesium
URINALYSIS: No
NEUROBEHAVIOURAL EXAMINATION: No - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes
Organ weights: liver, kidneys, adrenal glands, thymus, spleen, and testes of all animals.
Fixed in 4% formaldehyde: liver, kidneys, spleen, adrenal glands, heart, thymus, brain, sciatic nerve, mandibular salivary glands, sublingual salivary glands, stomach, mesenteric lymph nodes, testes, ovaries and gross lesions
HISTOPATHOLOGY: Yes
Control and high dose group: liver, kidneys, spleen, adrenal glands, heart, thymus, brain, sciatic nerve, mandibular salivary glands, sublingual salivary glands
All treatment groups: gross lesions - Statistics:
- Food consumption, body weight and body weight change, clinical chemistry and hematology (except differential blood count):
KRUSKAL-WALLIS h-test (Post test: MANN-WHITNEY U-test)
Terminal body weight, absolute and relative organ weights:
KRUSKAL-WALLIS h-test (Post test: WILCOXON-Test )
Results and discussion
Results of examinations
- Details on results:
- CLINICAL SIGNS AND MORTALITY
During the conduct of the study one female (750 mg/kg body .weight group) died intercurrently. However, this was attributable to gavage error and can therefore not be related to the test substance administration.
750 mg/kg bw:
- Ataxia was found in all male and female rats from the first test substance administration onward. One female rat of the high dose group showed lateral position and apathy after the 4th administration and died during the afternoon. Further clinical signs observed were piloerection in 4 females of the 750 mg/kg body weight group. In a few female animals lateral position, apathy and salivation occurred during the conduct of the study.
The clinical signs were observable after administration of the test substance throughout the working day; however, by the morning of the next day they were found to be reversible and reappeared only after a renewed substance administration
150 and 30 mg/kg bw: No clinical symptoms were observed
BODY WEIGHT AND WEIGHT GAIN
The body weight/body weight gain of the male and female rats of all dose groups corresponded to the values of the vehicle control group. The significant increased body weight gain on day 28 in male rats of test group 2 (150 mg/kg body weight) was assessed as being incidental.
FOOD CONSUMPTION
When compared with the untreated controls, the male and female rats of all dose groups showed no substance related differences regarding the amount of food consumed daily.
HAEMATOLOGY
No substance-related changes were observed in the hematological examinations of both sexes. No substance-related changes were observed in the
clotting analyses of both sexes.
CLINICAL CHEMISTRY
No substance-related changes were observed in the enzyme activities of both sexes.
In the highest dose group (750 mg/kg body weight) of both sexes the chloride concentrations in the serum were statistically significantly decreased when compared with the control. Moreover, in the serum of the high-dose females decreased potassium levels and in the serum of the males of test group 3 (750 mg/kg body weight) increased magnesium concentrations were detected. Although these findings are difficult to assign to a specific toxic effect, the changes in the electrolyte status are considered to be treatment-related.
At the end of the administration period statistically significantly increased cholesterol concentrations were observed in the peripheral blood of both sexes in the highest dose group. Furthermore, in the mid- and high-dose males the triglyceride levels were statistically significantly decreased compared to the control. The changes in cholesterol and triglyceride concentrations in the serum of the high-dose animals are assessed to be substance-related and are probably caused by a slight disturbance of lipid metabolism. However, the decreased triglyceride content in the serum of test group 2 (150 mg/kg body weight) males is not considered to be associated with the administration of the test article, since this finding is in the range of biological variation and is observed in one sex only.
PATHOLOGY
No substance-related changes were observed. In males of the 150 mg/kg bw group, the absolute liver weights were increased and the relative testes weights were decreased. Since no dose response relationship was evident, these effects were considered as not relevant. In females of the 750 mg/kg bw group, the mean absolute and relative liver weight was increased, but due to a incidental death the statistical power for a test was too weak; additionally, this effect was not supported by histopathological findings. Therefore, this result was considered as not relevant.
No morphological changes were seen in the brain or peripheral nerves. Thus, the clinical symptoms observed are most probably due to pharmacological or local irritating effects of the test substance but not due to permanent morphological alterations of the nervous system.
Effect levels
- Dose descriptor:
- NOAEL
- Remarks:
- systemic
- Effect level:
- 150 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Clinical signs (reversible within one day), effects on blood chemistry and changes in the electrolyte status seen at 750 mg/kg bw/d
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
FIRST PRETEST
500 mg/kg bw: Lethargy and atactic gait were observed in the first week
of the study, each time some hours after administration by gavage.
Increased absolute and relative kidney weights were observed in males
and decreased absolute and relative thymus weights in females.
100 mg/kg bw: Decreased absolute and relative thymus weights were
observed in the females
SECOND PRETEST
1000 mg/kg bw: One female died after 3 administrations by gavage.
Atactic gait, lethargy, piloerection and lateral position were observed
in the males, each time after administration, but not on the next
morning before the test substance administration. Lethargy and lateral
position were observed in all 3 females, each time after administration.
In addition, two rats showed atactic gait, one rat salivation and one
rat laboured respiration. However, all these findings were reversible
and no longer seen on the next morning before administration. The
females showed pilorection and anogenital and lower abdominal regions
smeared with urine, both after administration by gavage and also on the
next morning before administration.
15 mg/kg bw: No clinical findings
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.